Cesca Therapeutics Inc. (NASDAQ: KOOL) is focused on three target markets: cellular therapeutics; medical/diagnostic device development and commercialization; and cell manufacturing and banking. Cesca’s lead therapeutic technology platform, SurgWerks (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. For more information, visit the company’s website at www.cescatherapeutics.com.